Key points of investment

Company highlights: As one of the leading private ophthalmology service providers in Hong Kong and Guangdong Province, the company has international standards of ophthalmic medical service quality, an excellent team of doctors and an experienced management team. With these advantages, the company is expected to consolidate and further expand the existing regional market. At the same time, the company is the first foreign investor to establish a wholly-owned eye hospital in China. Shenzhen Xima Hospital is the first Hong Kong-funded private hospital established under CEPA. With the capital raised from this listing, the company will further expand the market in mainland China, expand to other cities across the country based on Beijing and Shenzhen, and expand to other cities across the country. Extended development will bring significant growth to the company.

Investment advice: The company has international quality advantages and has maintained steady and rapid growth of 20%-30% in recent years. Considering the broad development space of the private ophthalmology market, investors are advised to subscribe.

Risk warning: 1. Risk of changes in the management team; 2. Risk of changes in the doctor team; 3. The speed of extension is lower than expected; 4. The risk that reputation will be negatively affected; 5. The development rate of the original hospital is lower than expected